Gemici C
Dr Lutfi Kirdar Kartal Education and Research Hospital, Department of Oncology, Istanbul, Turkey.
Clin Oncol (R Coll Radiol). 2006 Dec;18(10):773-80. doi: 10.1016/j.clon.2006.09.005.
Tumour lysis syndrome (TLS) is an oncological emergency that results from massive cytolysis of malignant cells with a sudden release of their cellular contents, such as intracellular ions and metabolic by-products, into the systemic circulation. This syndrome is common in tumours with rapid cell turnover and growth rates, and in bulky tumours with high sensitivity to antineoplastic treatments. It is, therefore, a well-recognised clinical problem in haematological malignancies. It is rarely observed in solid tumours. Here, published studies are reviewed, beginning with the first report of TLS in solid tumours. Reported solid TLS cases are evaluated according to their common features and differences, and their similarities with those seen in haematological malignancies. Basic principles for the prevention and management of TLS are mentioned, with particular emphasis on solid tumours.
肿瘤溶解综合征（TLS）是一种肿瘤急症，它源于恶性细胞的大量细胞溶解，其细胞内容物（如细胞内离子和代谢副产物）突然释放到体循环中。这种综合征在细胞更新和生长速度快的肿瘤以及对抗肿瘤治疗高度敏感的巨大肿瘤中很常见。因此，它是血液系统恶性肿瘤中一个公认的临床问题。在实体瘤中很少观察到。在此，对已发表的研究进行综述，从实体瘤中TLS的首次报告开始。根据报告的实体TLS病例的共同特征和差异以及它们与血液系统恶性肿瘤中所见病例的相似性进行评估。文中提到了TLS预防和管理的基本原则，尤其强调了实体瘤方面。
